Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Gets FDA Clearance for MRSA/SA Molecular Test

NEW YORK (GenomeWeb News) – Cepheid has received US Food and Drug Administration clearance to market its Xpert MRSA/SA Skin and Soft Tissue Infection test, the firm said today.
The molecular test, which runs on the firm’s GenXpert System, is used for rapidly identifying methicillin-resistant Staphylococcus aureus and Staphylococcus aureus in skin and soft tissue infections. Like its Xpert MRSA test, which was cleared for marketing by FDA in April 2007, the MRSA/SA test can provide results in less than an hour, Cepheid said.
“The ability to detect MRSA or SA in less than one hour, versus two to three days with current culture methods, will enable clinicians to make real-time decisions as to the best course of treatment or management,” Cepheid CEO John Bishop said in a statement.
Cepheid is working on a variety of tests for hospital-acquired infections, including C. difficile and vancomycin-resistant Enterococcus, which it hopes to launch next year. It also is developing tests for Factors II and V in hemostasis testing.
Bishop noted at last week’s UBS Global Life Sciences Conference that the firm would release study data on its C. difficile test at the end of October.
Shares of Cepheid were down 3.3 percent at $14.12 in early Monday trade on the Nasdaq.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.